UBS Group’s Pulmatrix PULM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $30 | Buy |
+23
| New | +$55 | ﹤0.01% | 10252 |
|
|
2025
Q4 | – | Sell |
-129
| Closed | -$627 | – | 11034 |
|
|
2025
Q3 | $627 | Sell |
129
-5,334
| -98% | -$28.3K | ﹤0.01% | 9595 |
|
|
2025
Q2 | $37.7K | Buy |
5,463
+4,308
| +373% | +$29.7K | ﹤0.01% | 8008 |
|
|
2025
Q1 | $7.69K | Sell |
1,155
-3,765
| -77% | -$27.7K | ﹤0.01% | 8803 |
|
|
2024
Q4 | $34.3K | Buy |
4,920
+4,528
| +1,155% | +$18.7K | ﹤0.01% | 7525 |
|
|
2024
Q3 | $839 | Sell |
392
-3,447
| -90% | -$7.23K | ﹤0.01% | 8805 |
|
|
2024
Q2 | $7.41K | Buy |
3,839
+3,674
| +2,227% | +$7.1K | ﹤0.01% | 7855 |
|
|
2024
Q1 | $289 | Hold |
165
| – | – | ﹤0.01% | 8652 |
|
|
2023
Q4 | $307 | Sell |
165
-1,057
| -86% | -$2.02K | ﹤0.01% | 8738 |
|
|
2023
Q3 | $2.48K | Buy |
1,222
+127
| +12% | +$313 | ﹤0.01% | 7694 |
|
|
2023
Q2 | $2.94K | Sell |
1,095
-5,723
| -84% | -$16.1K | ﹤0.01% | 7678 |
|
|
2023
Q1 | $19.9K | Buy |
6,818
+2,446
| +56% | +$8.85K | ﹤0.01% | 7085 |
|
|
2022
Q4 | $17K | Buy |
4,372
+3,037
| +227% | +$11K | ﹤0.01% | 7866 |
|
|
2022
Q3 | $5K | Sell |
1,335
-364
| -21% | -$1.62K | ﹤0.01% | 9214 |
|
|
2022
Q2 | $8K | Sell |
1,699
-1,291
| -43% | -$6.81K | ﹤0.01% | 8337 |
|
|
2022
Q1 | $20K | Buy |
2,990
+1,895
| +173% | +$13.8K | ﹤0.01% | 7453 |
|
|
2021
Q4 | $10K | Hold |
1,095
| – | – | ﹤0.01% | 8793 |
|
|
2021
Q3 | $18K | Sell |
1,095
-636
| -37% | -$10.6K | ﹤0.01% | 7295 |
|
|
2021
Q2 | $36K | Buy |
1,731
+60
| +4% | +$1.22K | ﹤0.01% | 6747 |
|
|
2021
Q1 | $44K | Buy |
+1,671
| New | +$51.2K | ﹤0.01% | 6684 |
|
|
2020
Q3 | – | Sell |
-401
| Closed | -$14K | – | 8323 |
|
|
2020
Q2 | $14K | Buy |
401
+343
| +591% | +$10.9K | ﹤0.01% | 6797 |
|
|
2020
Q1 | $1K | Sell |
58
-682
| -92% | -$19.9K | ﹤0.01% | 7789 |
|
|
2019
Q4 | $13K | Buy |
740
+201
| +37% | +$3.19K | ﹤0.01% | 7149 |
|
|
2019
Q3 | $9K | Sell |
539
-99
| -16% | -$1.73K | ﹤0.01% | 7222 |
|
|
2019
Q2 | $12K | Buy |
638
+567
| +799% | +$12.3K | ﹤0.01% | 6953 |
|
|
2019
Q1 | $2K | Sell |
71
-174
| -71% | -$5.82K | ﹤0.01% | 7461 |
|
|
2018
Q4 | $12K | Buy |
245
+150
| +158% | +$11.1K | ﹤0.01% | 7146 |
|
|
2018
Q3 | $7K | Sell |
95
-42
| -31% | -$3.56K | ﹤0.01% | 7340 |
|
|
2018
Q2 | $12K | Buy |
137
+112
| +448% | +$10.9K | ﹤0.01% | 7039 |
|
|
2018
Q1 | $3K | Buy |
25
+8
| +47% | +$2.29K | ﹤0.01% | 7439 |
|
|
2017
Q4 | $5K | Sell |
17
-17
| -50% | -$5.77K | ﹤0.01% | 7389 |
|
|
2017
Q3 | $14K | Buy |
34
+17
| +100% | +$6.92K | ﹤0.01% | 6705 |
|
|
2017
Q2 | $8K | Buy |
+17
| New | +$9.18K | ﹤0.01% | 6919 |
|
|
2016
Q4 | – | Sell |
-19
| Closed | -$6K | – | 7975 |
|
|
2016
Q3 | $6K | Buy |
+19
| New | +$7.11K | ﹤0.01% | 7061 |
|
|
2016
Q1 | – | Sell |
-6
| Closed | -$5K | – | 8051 |
|
|
2015
Q4 | $5K | Buy |
6
+2
| +50% | +$1.81K | ﹤0.01% | 7699 |
|
|
2015
Q3 | $4K | Sell |
4
-6
| -60% | -$7.55K | ﹤0.01% | 7838 |
|
|
2015
Q2 | $19K | Buy |
10
+6
| +150% | +$11.6K | ﹤0.01% | 6920 |
|
|
2015
Q1 | $7K | Buy |
4
+1
| +33% | +$1.96K | ﹤0.01% | 7911 |
|
|
2014
Q4 | $4K | Buy |
+3
| New | +$6.4K | ﹤0.01% | 9120 |
|
Other funds holding PULM
VCM
SS
VFT
XT
TRCT
UBS Group's PULM Position: Q1 2026 in Review
UBS Group opened a new position in Pulmatrix (PULM) in Q1 2026: 23 shares worth $30. The stake represents ﹤0.01% of the portfolio and ranks #10252 among its holdings. This is a return to the name: UBS Group previously reported a position in PULM as recently as Q3 2025.
UBS Group first reported a position in PULM in Q4 2014 and has held it in 39 quarters since. The position peaked at $44K in Q1 2021. 15 funds tracked by Wall St. Rank hold PULM as of Q1 2026.
- UBS Group held 23 shares of Pulmatrix worth $30 as of Q1 2026.
- Pulmatrix was a new UBS Group position in Q1 2026.
- Pulmatrix made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10252 holding.
- UBS Group first reported a position in Pulmatrix in Q4 2014 and has held it in 39 quarters since.
- UBS Group's Pulmatrix position peaked at $44K in Q1 2021.
- 15 funds tracked by Wall St. Rank held Pulmatrix as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.